Latest Recruitment News

EDU Holdings reports a robust 36% increase in total student enrolments for Trimester 1, 2026, driven by strong growth in its higher education arm, Ikon Institute. The company is strategically shifting focus towards higher education amid regulatory changes impacting recruitment.

Integral Diagnostics Limited has reported a robust half-year performance, with revenues soaring 55.6% and EBITDA nearly doubling, driven by strong patient volume growth and successful integration of Capitol Health. The company also declared a fully franked interim dividend of 3.3 cents per share.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

Clarity Pharmaceuticals reports another metastatic prostate cancer patient achieving undetectable disease markers in its Phase II SECuRE trial, reinforcing promising efficacy and safety of its Cu-SAR-bisPSMA radiopharmaceutical.

Coronado Global Resources announces the resignation of CEO Douglas Thompson, triggering a leadership reshuffle including interim appointments and a shift in executive roles.

PeopleIN reported half-year earnings in line with expectations while strategically acquiring New Zealand’s Infrawork to bolster its infrastructure recruitment footprint across the Asia Pacific.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

LGI Limited reported robust half-year results for December 2025, showcasing strong revenue and profit growth alongside operational expansion and strategic debt repayment.

Paradigm Biopharmaceuticals has drawn down US$5 million from its Convertible Note Facility to fund the next phase of its global Phase 3 trial for knee osteoarthritis treatment, marking a key step as patient recruitment nears 50%.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Alligator Energy has completed commissioning of its Samphire pilot plant and is set to begin a four-month uranium field recovery trial, signalling a key step towards project development.